In a Barcelona laboratory, researchers have cracked a crucial code about how tiny cellular packets could one day help heal inflamed blood vessels—and it all comes down to sugar chains on the surface of these molecules.
Scientists at the Germans Trias i Pujol Research Institute (IGTP) have identified N-glycosylation—sugar modifications on the surface of proteins and lipids—as the key mechanism that allows extracellular vesicles derived from mesenchymal stromal cells to reduce inflammation. The discovery, published in the Journal of Extracellular Vesicles, reveals how these nanoscale particles interact with blood vessel walls and could reshape how we treat diseases caused by poor blood flow and chronic inflammation.
Extracellular vesicles are already attracting serious attention in nanomedicine circles. These vesicles, released by living cells naturally, show potential for treating inflammatory diseases and supporting tissue regeneration. One particularly promising application: intravenous administration to reduce the dangerous inflammation that develops in blood vessels after ischemia—when blood flow is cut off and tissues starve for oxygen.
But how exactly do these vesicles work their anti-inflammatory magic? The IVECAT research group, led by researchers including Dr. Marta Clos-Sansalvador and Dr. Marta Monguió-Tortajada, set out to find answers using an ingenious experimental approach. Rather than relying on standard laboratory models, they built an in vitro system that simulates actual blood flow. This dynamic environment allows researchers to watch how vesicles interact with inflamed endothelium—the inner lining of blood vessels—and how they influence monocytes, the immune cells that arrive first at sites of inflammation and determine what happens next.
The results were illuminating. Vesicles with intact N-glycosylation successfully reduced the recruitment of monocytes to inflamed blood vessel walls. More specifically, this protection worked through the MCP-1/CCR2 axis, a molecular signaling pathway that controls how immune cells migrate toward sites of injury. Under realistic flow conditions, the researchers observed that these properly glycosylated vesicles could prevent monocytes from rolling along and adhering to vessel walls—critical steps that must occur before these cells can breach the endothelial barrier and deepen inflammation.
"Flow experiments have been key to gaining a better understanding of how extracellular vesicles interact with inflamed endothelium in a setting that more closely reflects what happens inside blood vessels," Dr. Clos-Sansalvador explains. The conventional static models, her colleague Dr. Monguió-Tortajada notes, simply cannot capture the complex choreography of monocyte movement under shear forces. By developing this more physiologically relevant system, the team revealed how vesicles reduce monocyte extravasation—their escape through vessel walls—and thereby contain inflammation at its source.
The implications reach far beyond this single study. Understanding that surface glycosylation is a critical determinant of extracellular vesicle function opens doors to rational bioengineering. Future researchers could now design vesicles with enhanced targeting capabilities and more potent immunomodulatory effects, potentially turning these natural cellular messengers into precision therapeutic tools for ischemic stroke, heart attack, and chronic inflammatory conditions. This Barcelona breakthrough suggests that sometimes the smallest architectural details—sugar chains invisible to the naked eye—hold the keys to healing.